-
CStone Pharmaceuticals Reports 2024 Interim Results with Strategic Collaborations and Regulatory Milestones
•
CStone Pharmaceuticals, a biopharmaceutical company based in China and listed on the Hong Kong Stock Exchange (HKG: 2616), has reported its interim financial results for 2024, along with key business highlights. For the six months ending June 30, 2024, the company’s revenue reached RMB 254.2 million, which includes RMB 118.3…
-
Guangzhou-Based Bio-Thera Solutions Expands Market Presence with Biosimilars and Innovative Drug Approvals
•
Bio-Thera Solutions, a biotech company based in Guangzhou and listed on the Shanghai Stock Exchange (SHA: 688177), has reported its financial results for the first half of 2024. The company recorded a 27.85% year-on-year (YOY) increase in revenue, reaching RMB 402.29 million. This growth is likely due to the continued…
-
Ascentage Pharma’s 2024 Interim Results Highlight 477% YOY Revenue Growth and First-Ever Profitability
•
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced its 2024 interim results for the first half of the year, setting a new revenue record with a staggering 477% year-on-year (YOY) increase, reaching RMB 824 million (USD 115.4 million). The lion’s share of this revenue came from…
-
3SBio Inc. Reports 16% YOY Revenue Growth in 2024 Interim Financial Report, Highlighting Biomedicine Segment Strength
•
3SBio Inc., a China-based biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 1530), has reported its interim financial results for 2024. The company’s operating revenue for the period stood at RMB 4.389 billion (USD 614.6 million), reflecting a substantial year-on-year (YOY) increase of 16%. The adjusted EBITDA also…
-
Hangzhou Kang Ming’s ClouDr Posts Strong Financial Growth with Diversified Solutions and P2M Strategy
•
Hangzhou Kang Ming Information Technology Co., Ltd, trading under the moniker “ClouDr” on the Hong Kong Stock Exchange (HKG: 9955), has reported its financial results for the first half of 2024, demonstrating a robust year-on-year (YOY) increase of 17.9%, with total revenues reaching RMB 2.125 billion (USD 298 million). The…
-
WuXi Biologics Reports Flat Revenues with Growth in Non-COVID-19 Projects in 2024H1 Financial Report
•
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) from China, has released its unaudited financial report for the first half of 2024. The company’s revenues for the period were on par with the same period in 2023, hitting RMB 8.57 billion (USD 1.2 billion), which…
-
Sisram Medical Reports 2024 Interim Revenues with Growth in Key Regions and New Product Launches
•
Sisram Medical Ltd (HKG: 1696), an Israel-based subsidiary of the Fosun Pharmaceutical Group, has released its unaudited interim financial report for 2024, showing revenues of USD 168.7 million, a slight decrease of 1.7% year-on-year (YOY). The company’s regional revenue breakdown indicates growth in the Asia Pacific, Europe, Middle East, and…
-
Jiangsu Hengrui Pharmaceuticals Reports 21.78% YOY Revenue Growth and 48.67% Increase in Net Profit for H1 2024
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd, a leading pharmaceutical company based in China with shares traded on the Shanghai Stock Exchange (SHA: 600276), has announced its financial results for the first half of 2024. The company reported a robust revenue of RMB 13.601 billion, reflecting a 21.78% year-on-year (YOY) increase. The…
-
R&D Investments and Operating Cash Flows Highlight Resilience in Simcere Pharma’s H1 2024 Financial Report
•
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has reported its financial results for the first half of 2024, with revenues amounting to RMB 3.114 billion, marking a 7.9% year-on-year (YOY) decline. The innovative drug business contributed RMB 2.203 billion, representing approximately 70.7% of total revenues and reflecting an 8.7% YOY…
-
WuXi XDC Reports 67.6% YOY Revenue Growth and Expands Manufacturing with Singapore Plant
•
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has reported its financial performance for the first half of 2024, along with recent corporate developments. The company is dedicated to offering Contract Research, Development, and…
-
Chengdu Kanghua Biological Products Reports 16.81% YOY Revenue Growth in H1 2024 Financial Results
•
Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has reported its financial results for the first half of 2024, with revenues reaching RMB 741 million (USD 104 million), marking a significant year-on-year (YOY) increase of 16.81%. The net profits attributable to shareholders have risen…
-
CSPC Pharmaceutical Group Reports Moderate H1 2024 Revenue Growth with Patent Medicines Driving the Increase
•
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading China-based pharmaceutical enterprise, has announced its financial results for the first half of 2024, reflecting a modest year-on-year (YOY) revenue increase of 1.3%, totaling RMB 16.284 billion (USD 2.28 billion). The patent medicine segment demonstrated robust growth, with revenues rising by 4.8%…
-
WuXi XDC Accelerates Bioconjugate Drug Development with 67.6% YOY Revenue Increase in H1 2024
•
HONG KONG—WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has reported a remarkable financial performance for the first half of 2024, with revenues jumping 67.6% year-on-year to RMB 1.665 billion (USD 230 million). This…
-
Chengdu Kanghua Biological Products Soars with 16.81% YOY Revenue Growth in H1 2024 Report
•
CHENGDU—Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841) has reported a significant upswing in its financial performance for the first half of 2024, with revenues reaching RMB 741 million (USD 104 million), marking a 16.81% increase year-on-year. Net profits attributable to shareholders have also seen robust growth, climbing to RMB…
-
CSPC Pharmaceutical Group Reports Modest Gains in H1 2024 with Patent Medicines Driving Revenue
•
HONG KONG—CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced its financial results for the first half of 2024, with total revenues reaching RMB 16.284 billion (USD 2.28 billion), reflecting a 1.3% increase year-on-year. The patent medicine business proved to be a significant revenue driver, with sales climbing 4.8% YOY to…
-
CGP’s 2024 Interim Report Shows Robust Growth in Revenues and Profits, Highlighting R&D Focus
•
HONG KONG—China Grand Pharmaceutical and Healthcare Holdings Ltd (CGP; HKG: 0512) has released its interim financial report for 2024, revealing a 5.4% year-on-year increase in revenues to HKD 6.05 billion (USD 776.7 million) in constant exchange rate terms. The profit attributable to the company’s owners surged 51.4% year-on-year to approximately…
-
RemeGen Reports 75.6% Revenue Surge in H1 2024, Driven by Key Product Sales
•
RemeGen (HKG: 9995) has reported a robust performance in its first half of 2024, achieving revenues of RMB 742 million (USD 103.9 million), marking a significant 75.59% increase year-on-year. This growth was primarily fueled by heightened sales of its flagship products, telitacicept and disitamab vedotin. The company’s research and development…
-
Sino Biopharmaceutical Reports Record H1 Revenues of RMB 15.87 Billion, Net Profit Soars 139.7%
•
Sino Biopharmaceutical Ltd (HKG: 1177) reported robust financial results for the first half of 2024, generating revenues of RMB 15.87 billion (USD 2.2 billion), marking an 11.1% year-on-year increase and a record high for the company. Net profits surged to RMB 3.02 billion (USD 420 million), reflecting a remarkable 139.7%…
-
Gilead Buys Out Janssen’s Royalty Rights to Seladelpar for Primary Biliary Cholangitis Treatment
•
Gilead (NASDAQ: GILD)’s financial report for the second quarter of 2024, followed by an earnings call, has disclosed a significant transaction: the company has paid Johnson & Johnson’s Janssen division USD 320 million to acquire full royalty rights to the PPAR-delta agonist, seladelpar, a drug for which Gilead obtained global…
-
Legend Biotech CEO Addresses Biosecure Act Concerns Amid Q2 2024 Earnings Report
•
Legend Biotech Corporation (Nasdaq: LEGN), a leading Chinese biopharmaceutical company, has released its financial results for the second quarter of 2024. Amidst recent speculation about potential implications from the U.S. Biosecure Act, CEO Ying Huang addressed concerns during the earnings call. The U.S. House of Representatives’ committee on China had…
